{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:37:01Z","timestamp":1789605421951,"version":"build-2803163510"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Daytime symptoms, including negative mood, fatigue, and cognitive impairment, are core features and diagnostic criteria for insomnia disorder. Historically, assessment of these daytime insomnia symptoms has relied on retrospective questionnaires with varying recall periods and that may lack sensitivity to detect subtle change attributable to insomnia treatment.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To use smartphone-based ecological momentary assessment (EMA) to determine the effect of insomnia pharmacotherapy on daytime insomnia symptoms.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This was a double-blind, placebo-controlled randomized clinical trial. All procedures were conducted remotely between October 9, 2023, and August 8, 2024. Following baseline assessment, participants were randomized to suvorexant or placebo, including 2 nights at 10 mg then 14 nights at 20 mg. Participants completed the Daytime Insomnia Symptoms Scale (DISS) 4 times per day (ie, 64 administrations over 16 days) and a posttreatment assessment. Participants were recruited from an academic center. Inclusion criteria were individuals aged 60 to 85 years, diagnosed with chronic insomnia per clinical interview, with moderate to severe insomnia symptoms (Insomnia Severity Index [ISI] \u226515), and owning a smartphone. Exclusion criteria were major untreated medical or psychiatric condition, contraindications for a dual-orexin receptor antagonist, refusal to discontinue other insomnia medications, or severe obstructive sleep apnea. Data were analyzed between September 6, 2024, and October 28, 2025.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Suvorexant 20 mg nightly vs placebo.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary EMA measure was the DISS. During baseline and posttreatment assessments, participants also completed questionnaires assessing insomnia severity, sleepiness, fatigue, anxiety, and depression.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Participants included 40 older adults (mean [SD] age, 67.9 [5.4] years; 36 [90%] women), with 20 participants randomized to suvorexant and 20 to placebo. There were no dropouts. The overall completion rate for EMA surveys was 93.3%. Relative to placebo, suvorexant reduced insomnia severity (mean [SD] change in ISI, \u22129.6 [5.4] vs \u22125.5 [6.8]; estimate [SE], 4.1 [1.9];\n t<\/jats:italic>\n \u2009=\u20092.1;\n df<\/jats:italic>\n \u2009=\u200936;\n P<\/jats:italic>\n \u2009=\u2009.04, effect size, 0.66 [95% CI, 0.02 to 1.30]). Based on retrospective questionnaires, no statistically significant between-group differences in daytime insomnia symptoms were detected. Based on EMA, significant between-group differences were detected in subjective cognition (\u03c7\n 2<\/jats:sup>\n 4<\/jats:sub>\n \u2009=\u200911.12;\n P<\/jats:italic>\n \u2009=\u2009.03) and fatigue (\u03c7\n 2<\/jats:sup>\n 4<\/jats:sub>\n \u2009=\u200921.43;\n P<\/jats:italic>\n \u2009=\u2009.003) at 1 or more times of day.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this randomized clinical trial of older adults with insomnia, although traditional outcomes assessments detected no between-group differences, EMA was sensitive to detect effects of insomnia pharmacotherapy on daytime insomnia symptoms at various times of day, a critical gap in the literature.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT05908526<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.50186","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T16:00:29Z","timestamp":1767628829000},"page":"e2550186","source":"Crossref","is-referenced-by-count":1,"title":["Smartphone-Based Real-Time Assessment of Daytime Insomnia Symptoms With Suvorexant"],"prefix":"10.1001","volume":"9","author":[{"given":"Emerson M.","family":"Wickwire","sequence":"first","affiliation":[{"name":"Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Maryland School of Medicine, Baltimore"},{"name":"Department of Psychiatry, University of Maryland School of Medicine, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingsong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Departments of Biostatistics, University of Maryland School of Medicine, Baltimore"},{"name":"Department of Statistics, University of Maryland, College Park"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Maryland School of Medicine, Baltimore"},{"name":"Department of Statistics, University of Maryland, College Park"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine A.","family":"Wilckens","sequence":"additional","affiliation":[{"name":"Department of Psychology, Indiana Wesleyan University, Marion, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A.","family":"Steenbergh","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Buysse","sequence":"additional","affiliation":[{"name":"Department of Psychology, Indiana Wesleyan University, Marion, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avelino C.","family":"Verceles","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Maryland School of Medicine, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"zoi251344r2","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2020.101387","article-title":"Advancing a value framework for sleep: Update on economic aspects of cognitive-behavioral treatments for insomnia.","volume":"54","author":"Wickwire","year":"2020","journal-title":"Sleep Med Rev"},{"key":"zoi251344r3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev.clinpsy.3.022806.091415","article-title":"Ecological momentary assessment.","volume":"4","author":"Shiffman","year":"2008","journal-title":"Annu Rev Clin Psychol"},{"issue":"3","key":"zoi251344r4","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.sleep.2006.10.006","article-title":"Daytime symptoms in primary insomnia: a prospective analysis using ecological momentary assessment.","volume":"8","author":"Buysse","year":"2007","journal-title":"Sleep Med"},{"issue":"1","key":"zoi251344r5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/j.1365-2869.2008.00621.x","article-title":"Sleep and affect in older adults: using multilevel modeling to examine daily associations.","volume":"17","author":"McCrae","year":"2008","journal-title":"J Sleep Res"},{"issue":"3","key":"zoi251344r6","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/jsr.12024","article-title":"Ecological momentary assessment of daytime symptoms during sleep restriction therapy for insomnia.","volume":"22","author":"Miller","year":"2013","journal-title":"J Sleep Res"},{"key":"zoi251344r7","doi-asserted-by":"publisher","DOI":"10.1038\/s44323-024-00008-y","article-title":"Prior-night sleep predicts next-day symptoms over ten days among military personnel with sleep problems.","author":"Wickwire","journal-title":"Npj Biol Timing Sleep"},{"issue":"5","key":"zoi251344r8","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jagp.2023.01.020","article-title":"Smart phone\/ecological momentary assessment of sleep and daytime symptoms among older adults with insomnia.","volume":"31","author":"Wickwire","year":"2023","journal-title":"Am J Geriatr Psychiatry"},{"key":"zoi251344r9","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jpsychires.2021.02.012","article-title":"Ecological momentary assessment as a measurement tool in depression trials.","volume":"136","author":"Targum","year":"2021","journal-title":"J Psychiatr Res"},{"issue":"3","key":"zoi251344r10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.pain.2005.06.025","article-title":"Brief cognitive-behavioral therapy for temporomandibular disorder pain: effects on daily electronic outcome and process measures.","volume":"117","author":"Turner","year":"2005","journal-title":"Pain"},{"issue":"2","key":"zoi251344r11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1037\/0022-006X.72.2.317","article-title":"Targeted naltrexone treatment moderates the relations between mood and drinking behavior among problem drinkers.","volume":"72","author":"Kranzler","year":"2004","journal-title":"J Consult Clin Psychol"},{"issue":"23","key":"zoi251344r12","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1212\/WNL.0b013e31827688ee","article-title":"Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.","volume":"79","author":"Herring","year":"2012","journal-title":"Neurology"},{"issue":"7","key":"zoi251344r13","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.jagp.2017.03.004","article-title":"Suvorexant in elderly patients with insomnia: pooled analyses of data from phase III randomized controlled clinical trials.","volume":"25","author":"Herring","year":"2017","journal-title":"Am J Geriatr Psychiatry"},{"issue":"7","key":"zoi251344r14","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsac124","article-title":"Remote clinical research operations during COVID-19: lessons learned and recommendations.","volume":"45","author":"Adornetti","year":"2022","journal-title":"Sleep"},{"key":"zoi251344r15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.jad.2024.01.119","article-title":"Drug-induced depressive symptoms: an update through the WHO pharmacovigilance database.","volume":"350","author":"Li","year":"2024","journal-title":"J Affect Disord"},{"key":"zoi251344r1","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013","edition":"5th ed"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2843418\/wickwire_2026_oi_251344_1766511687.94604.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T16:00:31Z","timestamp":1767628831000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2843418"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.50186","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]}}}